Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Methylnaphthidate

From PsychonautWiki Archive
Revision as of 19:55, 27 November 2016 by >Unity
Jump to navigation Jump to search
Methylnaphthidate
Chemical Nomenclature
Common names Methylnaphthidate, HDMP-28
Substitutive name Methylnaphthidate
Systematic name Methyl (naphthalen-2-yl)(piperidin-2-yl)acetate
Class Membership
Psychoactive class Stimulant
Chemical class Phenidate
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 4 mg
Light 10 - 15 mg
Common 15 - 30 mg
Strong 30 - 50 mg
Heavy 50 mg +
Duration
Total 2 - 5 hours
Onset 1 - 10 minutes
Peak 1.5 - 2 hours
Offset 1.5 - 2 hours
After effects 1 - 8 hours



Insufflated
Dosage
Threshold < 4 mg
Light 4 - 8 mg
Common 8 - 14 mg
Strong 14 - 28 mg
Heavy 28 mg +
Duration
Total 90 - 180 minutes
Onset 3 - 6 minutes
Peak 1 - 2 hours
Offset 1 - 2 hours
After effects 1 - 2 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
MDMA
Cocaine
Summary sheet: Methylnaphthidate

Methylnaphthidate (HDMP-28) is a stimulant drug of the substituted phenethylamine and piperidine classes, and close analog of the commonly prescribed ADHD drug methylphenidate (Ritalin, Focalin). The two substances are believed to have very similar base pharmacological mechanisms but have been reported to display distinctive subjective effects that perhaps corresponds to their differing binding efficacies and monoamine reuptake inhibition ratios, similar to 4F-MPH.

Methylnaphthidate has little to no history of human usage prior to its availability by vendors on the online research chemical market.

Pharmacology

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Methylnaphthidate is thought to act primarily as a monoamine triple reuptake inhibitor, meaning it effectively boosts the levels of dopamine, noradrenaline and serotonin neurotransmitters throughout the brain by binding to and partially blocking the transporter proteins that normally clear these monoamines from the synaptic cleft. This allows these molecules to accumulate throughout the brain, particularly within the reward pathways in the brain, resulting in stimulating and euphoric effects.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

  • Stimulation
  • Dehydration
  • Appetite suppression
  • Increased heart rate - This component has been reported by some as being uniquely pronounced in the -phenidate family. These effects might owe themselves to increased free-circulating serotonin in the blood, which would lead to sustained agonism at serotonin-2b receptors on the heart.
  • Teeth grinding - This component can be considered to be present, but less intense when compared with that of MDMA.

Cognitive effects

After effects

The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:

Toxicity and harm potential

The toxicity and long-term health effects of recreational methylnaphthidate use do not seem to have been studied in any scientific context and the exact toxic and lethal dosages are unknown. This is because methylnaphthidate is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried methylnaphthidate suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent researchshould always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

In terms of its tolerance, methylnaphthidate can be used multiple days in a row for extended periods of time, but acute tolerance does exist and builds up gradually over repeated extended use. This results in the user requiring an increase in dosage to achieve the same effects.

Methylnaphthidatehas potential for abuse on par with that of amphetamine or MDMA due to its lack of significant tolerance, euphoric effects and action upon dopamine and serotonin transporters.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] & "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - 25x compounds are highly stimulating and physically straining. Combinations with Methylnaphthidate should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Methylnaphthidate may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is known to lower the seizure threshold[1] and combinations with stimulants may further increase this risk.
  • "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - This combination may increase the amount of neurotransmitters such as serotonin to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.[2]
  • MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
  • Cocaine - This combination may synergistically increase strain on the heart to dangerous degrees.
  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[3]
  • United States - HDMP-28 is not explicitly controlled in the US, but it could possibly be considered an analog of a Schedule II substance (methylphenidate) under the Federal Analog Act.
  • Switzerland - HDMP-28 is illegal in Switzerland as of December 2015.[4]

See also

References

  1. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  2. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  3. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  4. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.